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Background: The external quality assurance (EQA) process aims at establishing laboratory performance levels. Leading European
groups in the fields of EQA, Pathology, and Medical and Thoracic Oncology collaborated in a pilot EQA scheme for somatic
epidermal growth factor receptor (EGFR) gene mutational analysis in non-small-cell lung cancer (NSCLC).
Methods: EQA samples generated from cell lines mimicking clinical samples were provided to participating laboratories, each
with a mock clinical case. Participating laboratories performed the analysis using their usual method(s). Anonymous results were
assessed and made available to all participants. Two subsequent EQA rounds followed the pilot scheme.
Results: One hundred and seventeen labs from 30 countries registered and 91 returned results. Sanger sequencing and a
commercial kit were the main methodologies used. The standard of genotyping was suboptimal, with a significant number of
genotyping errors made. Only 72 out of 91 (72%) participants passed the EQA. False-negative and -positive results were the main
sources of error. The quality of reports submitted was acceptable; most were clear, concise and easy to read. However, some
participants reported the genotyping result in the absence of any interpretation and many obscured the interpretation required
for clinical care.
Conclusions: Even in clinical laboratories, the technical performance of genotyping in EGFR mutation testing for NSCLC can be
improved, evident from a high level of diagnostic errors. Robust EQA can contribute to global optimisation of EGFR testing for
NSCLC patients.
Assessment of epidermal growth factor receptor (EGFR) mutations
has become mandatory to choose the most active first-line
treatment for patients with advanced non-small-cell lung cancer
(NSCLC). Indeed, randomized phase III clinical trials have
demonstrated that first-line administration of an EGFR TKI results
in a prolonged progression-free survival as compared with
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chemotherapy in patients carrying EGFR mutations (Mok et al,
2009; Maemondo et al, 2010; Mitsudomi et al, 2010; Fukuoka et al,
2011; Zhou et al, 2011; Rosell et al, 2012). These studies have also
confirmed that EGFR mutations are a reliable marker that predicts
sensitivity to EGFR TKIs (Mok et al, 2009).
Activating mutations occur in exons 18 through 21 of the TK
domain of the EGFR gene, and either point mutations or in-frame
small deletions or insertions (Sharma et al, 2007; De Luca and
Normanno, 2010). Although more than 250 mutations of the
EGFR gene have been described to date, two mutations, a single
point mutation in exon 21, the L858R, and a series of small in-
frame deletions in exon 19, account for B90% of all EGFR
mutations (Sharma et al, 2007; Linardou et al, 2008). EGFR
mutations are strongly associated with defined clinical and
pathological features: they are far more frequent in female patients
as compared with male; in adenocarcinoma as compared with
other histological types; in non-smokers as compared with current
smokers or former smokers; and in East-Asian NSCLC patients as
compared with Non-East-Asian patients (Normanno et al, 2006).
External quality assessment (EQA) is a system of objectively
checking laboratory results by an independent external agency (van
Krieken et al, 2013). The main objective of an EQA programme is
to establish inter-laboratory comparability. In this respect, the
EQA process can identify latent systematic errors in methodology
that may not be revealed by a laboratory’s own internal QA
processes. Representatives from ETOP, ESMO, ESP, EMQN and
other leading European groups met in July 2010 to discuss a pan-
European approach to EQA for EGFR mutation testing in NSCLC.
In this paper, we present the results of this pilot EQA scheme for
EGFR testing that was completed in 2013.
MATERIALS AND METHODS
Organisation of the scheme. A meeting was organised in July
2010 by ETOP and EMQN to bring together a group of
professionals representing EMQN, ESP, ETOP, ESMO and other
leading European groups involved in NSCLC testing (see
Supplementary Information). From this group, a steering group
of five individuals was formed who planned, designed and assessed
the results of the pilot EQA scheme. The scheme was coordinated
and administered by the EMQN and three rounds were organised
within a period of 18 months. The workflow of the scheme process
is shown in Figure 1.
Validation of samples. The primary aim of this scheme was to
develop a flexible, scalable EQA scheme designed to assess issues
related to techniques and minimum detection limits used in
standard laboratory practice, focusing exclusively on the analytical
(that is, sample processing, genotyping) and reporting phases
(interpretation of the results in relation to the clinical context). To
enable this and to avoid the significant challenges of sample
heterogeneity in real tissue samples, 20 artificial materials were
used composed of formalin-fixed paraffin-embedded (FFPE) cell
line samples. These EQA materials were designed to mimic real
tissue samples as closely as possible and contained homogenous
mixtures of mutant vs wild-type cell lines at a range of different
allelic ratios. The paraffin blocks were cut and 10 mm sections
placed in eppendorf tube at the Pathology department of the VU
University Medical Centre in Amsterdam, The Netherlands, by Dr
Erik Thunnissen. H&E (4 mm) sections were used to estimate the
number of tumour cells. In each EQA sample section, at least 200
nuclei were present (usually 4300), roughly mimicking the
amount of cells from a small NSCLC biopsy.
For each EQA sample, one 10-mm-thick section was sent by
EMQN to each of the three validating laboratories for mutational
analysis in a blinded fashion. Different sections from the block
were analysed for EGFR mutation status to ensure that the
mutation was homogeneously represented within each block. The
validating laboratories independently analysed the samples by
using three different approaches: direct sequencing of the PCR
product for exons 18–21 mutations; fragment analysis for exon 19
deletions and an allelic discrimination-based real-time PCR assay
for the L858R mutation in exon 21; and the Therascreen EGFR
RGQ kit (Qiagen, Hilden, Germany), reporting the results directly
to the EMQN.
The allelic ratios of mutations in each sample used in rounds 2
and 3 were accurately quantified by a commercial sponsor
(Horizon Diagnostics, Cambridge, UK) using droplet digital PCR
(ddPCR) on a BioRad QX100 (Hercules, CA, USA) platform.
Genomic DNA (gDNA) was extracted from FFPE sections on the
Promega (Madison, WI, USA) Maxwell System using the Maxwell
16 FFPE Plus LEV DNA purification kit, according to the
manufacturer’s protocol. Quantification was performed using a
Promega QuantiFluor dsDNA assay kit, according to the
manufacturer’s protocol. ddPCR was performed using Taqman
custom SNP 40 primer/probe assays (Life Technologies,
Carlsbad, CA, USA) to assess the frequency of each mutation
with the exception of the p.(E746_A750) assay, which was designed
in-house. DNA (40 ng) was added to each ddPCR reaction.
Reactions were performed in quadruplicate and droplets were
generated using a Droplet Generator according to the manufac-
turer’s instructions. PCR was performed on a standard thermo-
cycler using previously optimised, assay-specific cycling conditions.
Droplets were analysed using a QX100 Droplet Reader as described
in the manufacturer’s instructions. Data from at least 45 000
useable droplets were collected for each sample. Formalin-fixed
paraffin-embedded reference standards (Horizon Diagnostics)
were included as assay controls.
Registration of participant laboratories and shipment of
samples. Laboratories that performed EGFR mutational analysis
were invited to participate in the EQA via an open call from the
EMQN in conjunction with the ESP, ETOP and ESMO. Participating
laboratories registered via the EMQN website (European Molecular
Genetics Quality Network (EMQN), 2014), and were requested to
perform DNA extraction and analysis using their routine method. In
each round, 10 samples (one 10-mm-thick section for each) with
accompanying mock clinical referral information were sent to
participating laboratory. Each laboratory was identified only by a
unique EMQN ID code to avoid exchange of information between
participants and minimise bias in the results’ interpretation process.
The laboratories were given 8 weeks to complete their analyses and to
submit the results of genotyping to the EMQN website. The centres
were requested to provide information on the technique used for
mutational analysis and metrics relating to their experience of
performing EGFR mutational analyses.
Evaluation of results. The scheme included three rounds: the first
was restricted to a maximum of 30 labs to establish proof of
principle and validate the materials. A subsequent second round of
the scheme was organised with no restriction on participation.
Laboratories that failed the second round were provided with
another set of samples in a restricted third round. The steering
group evaluated the results according to a pre-defined scoring
system. The scoring system assigned two points to correct genotype
and zero points to false-positive or -negative results (Table 1).
Errors in mutation nomenclature that might lead to misinterpreta-
tion of the results (for example, stating ‘deletion’ without specifying
the exon in which the deletion occurs) were assigned 1.50 points.
This deduction was applied only once for each center, generally to
the first sample for which the error was found. One point was
awarded for cases in which the genotype was mispositioned or
miscalled: this error sometimes occurs with exon 19 deletions, for
which it might be difficult to define the precise base or amino acid
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in which the deletion starts or ends. If a test failed giving no result
on the sample (analytical failure), then the lab received 1.00 point
for that sample. The threshold to pass the EQA was set at a total
score for the 10 samples ofX18 out of 20 (Thunnissen et al, 2011)
– laboratories with a genotyping scoreo18 were classified as poor
performers (applied to rounds 2 and 3 only). Performance in the
assessment of clinical interpretation and reporting did not
contribute to poor performance.
RESULTS
Selection of the samples for the EQA. The first step of the EQA
scheme was the selection and the validation of the samples. Twenty
materials were manufactured by Dr Thunnissen by mixing four
lung cancer cell lines (A549, EGFR wild type), H1650 (EGFR,
p.(E746_A750del), H1975 (EGFR, p.(T790M), p.(L858R)) and
SW48 (p.G719S). Cell lines with mutations were serially diluted
into A549 or SIHA cells at different ratios relevant to establishing
the analytical sensitivity of the tests used by labs. Each material was
validated in three different reference laboratories using different
techniques to confirm the genotype and the results showed that the
mutations were detectable at all the designated ratios, dependent
on the technology used (Table 2). A good yield of gDNA was
obtained from all the samples. In addition, there was complete
concordance on the EGFR mutational status of the selected
specimens and therefore all were selected for use in the quality
assessment scheme with samples A1–A10 used for the pilot, and
B1–10 and C1–C10 in subsequent rounds 2 and 3.
To accurately establish quantitative measurements of the allelic
frequencies of the EGFR mutations, all 10 EQA samples (Table 2;
samples B/C1–B/C10) used in rounds 2 and 3 were analysed on a
ddPCR platform (BioRad QX100). Three of the samples had allelic
frequencies higher than expected (C3, C8 and C9), two were lower
(C2 and C10) and in one (C5) it was not possible to establish the true
value due to insufficient availability of sample material (Table 3).
First round proof of principle pilot scheme. Twenty-nine
laboratories registered from 13 countries, and 25 participated in
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Figure 1. Workflow of the EQA scheme process.
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the pilot EQA scheme (4 labs withdrew due to customs sample
importation problems), which was run in fourth quarter of 2011.
A set of 10 samples were sent to the laboratories (Table 2; samples
A1–A10). All the participating laboratories submitted results
within the 8-week time frame. The main methodology used by
the participants was PCR/sequencing (n¼ 10 laboratories; 34%)
and real-time PCR (n¼ 10; 34%) (Figure 2).
Two analytical errors (false-negative results) were observed.
A further five laboratories made process errors (sample swaps) that
resulted in an additional 24 genotype errors. In all cases, the
genotypes were correct, but reported for the wrong sample.
Therefore, 92% of the false-negative results were concentrated in
five laboratories. No false-positive results were reported. The
materials performed well and there were no analytical test failures.
As this was designed to ascertain proof of principle, we did not
apply a measure of successful laboratory performance. The pilot
established that the scheme design and methods used were
acceptable for use in a larger scheme.
Second round. One hundred and seventeen laboratories from 30
countries registered, and 101 participated in the second round (due
to customs issues we were not able to get samples to 16 labs), run
in the second quarter of 2012. Ninety-one laboratories submitted
results within the 8-week time frame – the remaining 10 labs gave
Table 1. Scoring system
Criteria Marks Scheme rounda (samples)
Genotyping
Correct genotype 2.00 A to C (all samples)
Incorrect genotype (false positive or false negative) 2.00 A to C (all samples)
Genotype mispositioned or miscalled (e.g., incorrect base/amino acid detected) 1.00 A to C (all samples)
Error in the nomenclature that might lead to misinterpretation of the results 0.50b A to C (all samples)
Biological/clinical interpretation
The mutation is predicted to be a sensitising mutation to EGFR TK inhibitors (TKI). Comment only B (1, 4)
The mutation is predicted to confer resistance to EGFR TK inhibitors (TKI). Comment only B (9)
General
Reference sequence and version indices not used, incorrect or inconsistent. 0.50b B (1, 4, 9) only
No description of assay used and its limitations 0.50b B (1, 4, 9) only
Analytical failure giving no test result 1.00 B (1, 4, 9) only
No statement present on estimated percentage of tumour cells within the sample Comment only B (1, 4, 9) only
Abbreviation: TK¼ tyrosine kinase.
aPilot round (A), second round (B) and third round (C).
bDeduction applied only once.
Table 2. Validation of EQA materials
Sample
no. PCR/sequencing Therascreen
Fragment analysis/real-time
PCR
Round no./sample
no.a
1 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); p.(L858R) p.(T790M); p.(L858R) A1
2 c.2235_2249del, p.(E746_A750del) p.(E746_A750del) p.(E746_A750del) A2
3 Wild type Wild type Wild type A3
4 Wild type Wild type Wild type A4
5 c.2235_2249del, p.(E746_A750del) p.(E746_A750del) p.(E746_A750del) A5
6 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); p.(L858R) p.(T790M); p.(L858R) A6
7 c.2235_2249del, p.(E746_A750del) p.(E746_A750del) p.(E746_A750del) A7
8 Wild type Wild type Wild type A8
9 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); p.(L858R) p.(T790M); p.(L858R) A9
10 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); p.(L858R) p.(T790M); p.(L858R) A10
11 c.2235_2249del, p.(E746_A750del) p.(E746_A750del) p.(E746_A750del) B1 and C8
12 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); c.2573T4G, p.(L858R) p.(T790M); c.2573T4G, p.(L858R) B2 and C3
13 c.2235_2249del, p.(E746_A750del) p.(E746_A750del) p.(E746_A750del) B3 and C9
14 Wild type Wild type Wild type B4 and C1
15 Wild type Wild type Wild type B5 and C4
16 Wild type Wild type Wild type B6 and C6
17 Wild type Wild type Wild type B7 and C7
18 c.2155G4A, p.(G719S) p.(G719S) p.(G719S) B8 and C10
19 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) p.(T790M); p.(L858R) p.(T790M); p.(L858R) B9 and C5
20 c.2155G4A, p.(G719S) p.(G719S) p.(G719S) B10 and C2
Abbreviation: EQA¼ external quality assessment.
aEQA scheme rounds – first (A), second (B) and third (C).
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no reason why they did not submit results. A different set of
samples from those used in the pilot first round were sent to the
laboratories with the emphasis being on the inclusion of mutations
at allelic frequencies that would challenge the analytical sensitivity
of all the commonly used technologies (Table 2; samples B1–B10).
A code number different from the one assigned in the first round
was given to the samples. In addition to the genotype results, all
participating laboratories were also required to submit for
assessment copies of their clinical reports for three samples (B1,
B4 and B9).
The main methodology used by the participants was PCR/
sequencing (n¼ 35 laboratories; 39%) and real-time PCR (n¼ 17;
18.6%; Figure 2). It was common for labs to use a combination of
different methodologies in their testing process (Table 4).
A variety of different errors were detected by the second scheme
round, including 74 (8.1%) genotype errors (false-positive (n¼ 13;
1.5%), false-negative (n¼ 61; 82.4%) and a combination of false-
negative and -positive results (n¼ 1; 1.4%)), as well as analytical
test failures (n¼ 31; 3.4%), mispositioning of the genotype (n¼ 7;
0.8%) and significant errors in the mutation nomenclature (n¼ 36;
3.9%). Two samples (B2 and B8) gave a disproportionately
high error rate compared with the other samples used in this
round (Table 5), with 94.1% of errors for B2 made by labs using
PCR/sequencing vs 40.7% of errors for sample B8 made by labs
using a version of the Therascreen EGFR kit (Qiagen). Laboratories
did not lose marks if the declared limitations of their assay meant
that they would not detect a particular mutation, at the given
frequency used in the EQA materials. Eighteen laboratories
(19.8%) from 13 countries with a total score below 18 did not
pass the second round and were thus classified as poor performers
– 72.2% of these labs used PCR/Sequencing as their main
diagnostic test for EGFR mutation status. The interpretation of
the test result relative to the clinical referral was reviewed with
laboratories receiving comments on their performance, but no
marks assigned.
Overall, 46 (50.5%) of the laboratories had a score X18 in the
second round and passed the EQA. All laboratories received a
certificate of participation that displayed their performance in the
scheme.
Third round. The 18 laboratories that did not pass the second
round were given the opportunity to participate in a third round.
One laboratory was unable to participate due to problems with
customs sample import permissions. The same set of samples used
in the second round was sent to the laboratories in the third
quarter of 2012 (Table 2; samples C1–C10). To obscure the sample
identity from the labs, a different code number from the one
assigned in the second round was given to the samples. Only the
genotyping result was assessed for each of the 17 laboratories that
returned results.
A total of 18 (10.6%) genotyping errors (reported false-positive
(n¼ 1; 5.5%) and false-negative results (n¼ 13; 94.4%)) were
made, as well as analytical test failures (n¼ 3; 1.8%). Eight
laboratories (47.1%) missed the same mutation in identical samples
in rounds 2 and 3 (for example, B3/C9, n¼ 1; B9/C5, n¼ 2;
B8/C10, n¼ 5), indicating a failure of their assay for a particular
mutation. Three laboratories (17.6%) had a pattern of errors,
indicating a more general assay validation problem. Four
laboratories (23.5%) did not pass the third round and scoredo18.
Overall, all 17 laboratories (100%) improved their performance
compared with the second round, with 6 (35.3%) labs getting the
correct result for all 10 samples.
DISCUSSION
The clinical significance of somatic aberrations in oncology has
seen rapid progression in the last couple of years with the
Table 3. Results from quantitative material validation
Confirmed allelic frequency (%)b
Sample no. EGFR mutation resulta
Estimated allelic
frequency (%) p.(G719S) p.(E746_A750del) p.(T790M) p.(L858R)
B4, C1 Wild type 0 0 0 0 0
B10, C2 c.2155G4A, p.(G719S) 25 19.5 0 0 0
B2, C3 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 10: 10 0 0 19.3 19.1
B5, C4 Wild type 0 0 0 0 0
B9, C5 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 50: 50 0 0 c c
B6, C6 Wild type 0 0 0 0 0
B7, C7 Wild type 0 0 0 0 0
B1, C8 c.2235_2249del15, p.(E746_A750del) 25 0 41.2 0 0
B3, C9 c.2235_2249del15, p.(E746_A750del) 5 0 15.3 0 0
B8, C10 c.2155G4A, p.(G719S) 10 8.3 0 0 0
aExons 18–21.
bConfirmed by droplet digital PCR.
cNot measured due to insufficient material.
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correlation of treatment-related outcomes to gene alterations
(Normanno et al, 2013). The rapid development and approval
for use of therapeutic drugs based on mutational tests has
represented a significant innovation for medical oncology, but
also a major challenge for oncologists, pathologists and clinical
scientists. Companion diagnostics and related guidelines have
traditionally lagged behind such clinical indications for a variety of
reasons. Although EQA schemes are running for the KRAS
(sporadic colorectal cancer) and BRAF (malignant melanoma)
genes, such schemes for EGFR are further complicated by the
diverse spectrum of mutations, tumour heterogeneity and issues
pertaining to the availability of appropriate biological material for
use as EQA samples. For this reason, ESMO, ETOP, ESP and other
stakeholders collaborated with the EMQN to develop an integrated
approach to offer EQA for EGFR mutation testing in NSCLC to
laboratories around the world. The purpose of the scheme is the
provision of accurate and reliable EGFR testing for patients by
assuring parity of test outcomes among participating laboratories
from around the world.
Different types of samples can be used for this type of EQA (van
Krieken et al, 2013). In the majority of existing schemes, FFPE
patient biopsy samples have been used (Bellon et al, 2011; Deans
et al, 2011; Thunnissen et al, 2011; Normanno et al, 2013).
Although this type of sample enables the complete analytical
pathway to be assessed ensuring a closer relationship between the
EQA and routine clinical activity, it is limited by the amount of
human tissue that is available and issues related to transport of
samples across national borders. For this scheme, we developed a
different approach and used artificial materials composed of FFPE
cell lines to allow us to provide exactly the same sample to all the
participating laboratories, even when these were numerous. In
addition, it was possible to generate homogenous samples with
variable content of mutant alleles by mixing wild-type and mutant
cells and to use them to uncover hidden weaknesses in test
performance (sensitivity, specificity). This EQA scheme assessed
both the genotyping, and the interpretation of the clinical
significance of the results. Other EQA schemes that employed
tumour samples have also addressed the pre-analytical phase, with
laboratories being required to assess the percentage of neoplastic
cells and to perform dissection if needed. However, scoring of this
phase is not easy, as no consensus on the estimation of tumour cell
content has been reached and a huge variability has been reported
in previous EQA schemes (Thunnissen et al, 2011; van Krieken
et al, 2013). Our approach is similar to that described by
Normanno et al (2013) as it reduces the inter-laboratory variability
related to the type of technique used for the dissection and allows a
comparative evaluation of the sensitivity and specificity of the
methods used for the mutational analysis. We used a total of 10
samples for each round of the scheme as has been suggested as the
adequate number of cases for proficiency testing in this area of
pathology (Thunnissen et al, 2011).
Overall, the results of the EQA suggest that there is more work to
be done if laboratories are to ensure that the quality of their EGFR
mutation testing meets an acceptable standard, as only 72 out of 91
(72%) of the laboratories passed the EQA and is in line with the
findings of other similar EQA schemes (Deans et al, 2013). The
threshold that was used (X18 points) is comparable with that of the
majority of other EQA schemes in this field (van Krieken et al,
2013). We weighted the marking of the errors’ type differently
depending on its implications for the patient. Errors resulting in no
diagnosis (analytical failures) or no change in diagnosis (different
mutation) were marked more leniently (deduction of 1.00 mark)
when compared with those that resulted in the wrong diagnosis for
the patient (false-negative or false-positive results; deduction of 2.00
marks). Given the potentially significant clinical consequences for
the patient of any error, we propose to change the threshold criteria
to418 points (Normanno et al, 2013) in future schemes to ensure
that any significant errors are picked up in the performance data.
The materials we used in the scheme allowed us to control for
some of the causes of variation seen in other EQA schemes, such as
influence of fixative on DNA quality (Bellon et al, 2011). However,
our results show that not all laboratories are able to produce EGFR
mutation test results to a high standard. At least 1 in 10 samples is
genotyped incorrectly in419% of laboratories (round 2), although
there is evidence to show that this does improve with continued
participation (round 3). In the first round proof of principle EQA,
we identified five laboratories that made systematic errors in their
pre or post-analytical processes. The way the sample blocks were
labelled may have contributed to these errors, but it is impossible
to identify the true root cause from our data. However, the
outcome of these errors was that the correct results were reported
for the wrong patients, indicating a failure of their quality
management system.
False-negative and false-positive results were the main sources
of genotyping error in the scheme. Both these results are extremely
harmful for NSCLC patients. In fact, a negative result will lead to
treatment of an EGFR-mutant patient with chemotherapy as first
line of therapy, which is less effective as compared with EGFR TKIs
in this subgroup of patients (Mok et al, 2009). On the other hand,
false-positive findings will lead to treatment of EGFR wild-type
patients with EGFR TKIs that have been shown to be detrimental
as first-line treatment in this subgroup of patients, who benefit more
from first-line chemotherapy (Mok et al, 2009; Fukuoka et al, 2011).
False-negative results accounted for 85% of all the genotype
errors made in the scheme and might be due to the low sensitivity
of the method used for mutational analysis. PCR/sequencing was
the most common method used in the scheme for scanning to
detect point mutations. The major disadvantage of sequencing is
that it is not very sensitive (Angulo et al, 2010), especially in
samples with low tumour cell content. Real-time allele-specific
tests, such as Qiagen’s Therascreen EGFR kits, are much more
Table 4. EGFR testing methodological combinations used by labs in
round 2
Methodological combinations Count
Pyrosequencingþ fragment length analysis 3
Pyrosequencingþ high-resolution melting 1
Pyrosequencingþ high-resolution meltingþ fragment length
analysisþSNaPshot kit
1
PyrosequencingþNextGen sequencing 1
Pyrosequencingþ Therascreen kit 1
SequencingþAmoyDx kit 1
Sequencingþdenaturing capillary electrophoresis 1
Sequencingþ fragment length analysis 4
Sequencingþ fragment length analysisþhigh-resolution melt
analysisþ restriction fragment length polymorphism
1
Sequencingþ fragment length analysisþhigh-resolution melt
analysisþSNaPshot
1
Sequencingþ fragment length analysisþ restriction fragment
length polymorphism
1
Sequencingþ fragment length analysisþTaqman 1
Sequencingþhigh-resolution melting 4
SequencingþMassArray analysis 1
Sequencingþpyrosequencing 1
Sequencingþpyrosequencingþhigh-resolution melting 2
Sequencingþ restriction fragment length polymorphism 1
Sequencingþ single-strand conformational analysis 1
SequencingþTaqmanþPNA clamp 1
SequencingþTherascreen kit 5
SequencingþTherascreen kitþCAST PCR 1
SNaPshotþ single-strand conformational analysis 1
Therascreen kitþ fragment length analysisþ SNaPshot kit 1
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sensitive and specific, but only test for a subset of common
mutations (Lopez-Rios et al, 2013).
However, it is difficult for us to draw strong conclusions from this
scheme about the errors made using the different technologies due
to the lack of detailed data provided by the labs on exactly which
methods were used for each sample, except for samples B2/C3 and
B8/C10 that gave a disproportionately high error rate compared
with the other samples used. We hypothesised that our estimates of
mutational allelic frequency in the samples used in rounds 2 and 3
were inaccurate possibly due to EGFR gene copy number variation.
We therefore undertook further quantitative validation on these
samples using ddPCR to establish the true allelic frequency
(Hindson et al, 2011). This innovative approach enabled us to
establish that in three of the samples the true value was higher than
expected, and for the other two samples lower than expected.
However, crucially for two samples (B2/C3 and B8/C10), the value
established by ddPCR is very close to the expected minimum level of
methodological sensitivity (for example, 15% for Sanger sequencing,
and 5.43% for the p.(G719S) mutation as defined in version 1 of the
Qiagen Therascreen kit packaging insert). We speculate that latent
problems with the pre-analytical processes used by these labs (for
example, poor recovery of DNA, inaccurate DNA quantification)
resulted in false-negative results due to suboptimal analytical
conditions. These include insufficient method validation, misinter-
pretation of raw data, lack of awareness of assay limitations, sample
contamination and poor in-house assay design. Nevertheless, all of
the mutations were identified by the validating laboratories using a
range of different methodologies used by the participant labora-
tories. These findings confirm that every laboratory should be
undertaking an appropriate test validation or verification to define
the limits of detection and measurement uncertainty of the
techniques they are using. This is a requirement for all labs that
are accredited to the ISO 15189:2012 standard (International
Organisation for Standardization (ISO), 2010).
A fundamental aspect of all diagnostic testing is the accurate
reporting of the results. The quality of reports submitted was
acceptable with a large proportion being comprehensive, stand-
alone documents containing most of the basic core elements.
However, the report is meaningless if the referring clinician cannot
easily extract the relevant information. Therefore, it is essential that
that the report is clear, concise and easy to read. Many of the
reports obscured the take home message and there was often a lack
of clarity and balance between the test information and the clinical
context. Standardisation of the reporting and naming of mutations
is also important and we assessed labs against the nomenclature
guidelines from the Human Genome Variation Society (HGVS)
(Human Genome Variation Society (HGVS), 2014). For example,
we considered that it was not acceptable to report the amino acid
change only, as redundancy in the genetic code means that
different changes at the nucleotide level can result in the same
change at the amino acid level.
In conclusion, the results of this EQA scheme suggest that the
technical quality of EGFR mutational analysis could be improved
as evidenced from a high level of diagnostic errors. Overall, the
standard of reporting was acceptable. These findings also underline
the importance of EQA as a mechanism to reveal errors in
methodology and to ensure an adequate quality of molecular
testing. Regular participation in EQA should be seen as a routine
part of the diagnostic testing process for all labs helping to improve
and standardise their processes. We have established a model for a
robust and scalable EQA that can contribute to global optimisation
and improvements in the overall quality of EGFR testing for
patients with NSCLC.
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Table 5. Genotyping errors
False
positive
False
negative
Sample no. EGFR mutation resulta
Samples
tested Aa Ba Ca Aa Ba Ca
Total
errors
Error rate
(%) Round
1 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 23 0 4 4 17.4 A1
2 c.2235_2249del, p.(E746_A750del) 24 0 0 0 0.0 A2
3 Wild type 24 5 0 5 20.8 A3
4 Wild type 23 5 0 5 21.7 A4
5 c.2235_2249del, p.(E746_A750del) 24 0 5 5 20.8 A5
6 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 24 0 5 5 20.8 A6
7 c.2235_2249del, p.(E746_A750del) 24 0 1 1 4.2 A7
8 Wild type 23 0 0 0 0.0 A8
9 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 23 0 0 0 0.0 A9
10 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 24 0 1 1 4.2 A10
11 c.2235_2249del, p.(E746_A750del) 107 1 0 1 0 2 1.9 B1 and C8
12 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 107 2 0 16 1 19 17.8 B2 and C3
13 c.2235_2249del, p.(E746_A750del) 100 2 0 3 4 9 9.0 B3 and C9
14 Wild type 104 0 1 0 0 1 1.0 B4 and C1
15 Wild type 103 2 0 0 0 2 1.9 B5 and C4
16 Wild type 104 2 0 0 0 2 1.9 B6 and C6
17 Wild type 103 2 0 0 0 2 1.9 B7 and C7
18 c.2155G4A, p.(G719S) 104 2 0 25 10 37 35.6 B8 and C10
19 c.2369C4T, p.(T790M); c.2573T4G, p.(L858R) 106 0 0 7 2 9 8.5 B9 and C5
20 c.2155G4A, p.(G719S) 104 0 0 9 0 9 8.7 B10 and C2
aExternal quality assessment scheme rounds – first (A), second (B) and third (C).
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